Symbiosis | The Assurance of Regulatory Compliant, GMP Aseptic Manufacturing

Symbiosis has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber.

Explore Symbiosis' aseptic capabilities.

Symbiosis Pharmaceutical Services (Symbiosis), a global contract development and manufacturing organisation (CDMO) specialising in the GMP sterile fill-finish manufacturing of injectable drug products, has announced the appointment of Joanne Anderson as its Chief Commercial Officer.

Symbiosis Pharmaceutical Services has manufactured their first 10,000 vial batch at the company’s new facility in Stirling, UK.

Our purpose-built MHRA-licenced manufacturing facility has delivered over 1000 projects for clinical and small-scale commercial products. Our seasoned experts can help guide you through your next manufacturing project. The fundamental aim at Symbiosis is to meet your most demanding timelines by offering access to manufacturing slots within weeks, not months, and ensuring that your critical project is delivered on time, to the highest quality standard.

Symbiosis has been formally presented with a 2025 King’s Award for Enterprise in the International Trade category, the highest official accolade for British businesses. 

Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable drug products, has strengthened its business development team in the US with the dual appointments of Kevin O’Brien and LeeAnn Nguyen as Vice Presidents of Business Development for North America, and North America and Asia respectively.

Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable drug products, has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland.

Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable drug products, has appointed Wendy Cook as a Qualified Person (QP) to further strengthen its regulatory and quality leadership team.

Symbiosis Pharmaceutical Services, a global contract manufacturing organisation (CMO), today announced the successful completion of its 1,000th sterile drug product batch, marking a significant milestone in its mission to accelerate access to life-changing medicines worldwide.

Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in sterile manufacture of injectable drug products, has appointed Angelika Rublack as Senior Business Development Manager to support its expanding global client base and drive growth across several territories.

Symbiosis Pharmaceutical Services (Symbiosis), a global biopharmaceutical Contract Manufacturing Organisation (CMO) specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category, the UK’s highest official accolade for British businesses.

Symbiosis Pharmaceutical Services (Symbiosis), a global sterile fill/finish contract manufacturing organisation (CMO) has successfully completed its latest audit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), following an inspection of its new GMP manufacturing facility.

 
Symbiosis Pharmaceutical Services, a leading Contract Manufacturing Organisation (CMO) specialising in sterile GMP manufacturing of biopharmaceuticals, has been recognised by EcoVadis, the globally trusted provider of business sustainability ratings.

Global contract manufacturing organisation (CMO) Symbiosis Pharmaceutical Services has successfully completed its latest inspection by the US Food and Drug Administration (FDA) of its facilities in Scotland.

Symbiosis Pharmaceutical Services Ltd. announced the purchase of new premises in Stirling, Scotland, UK. The new facility and service extension project, supported by a grant from Scottish Enterprise totalling £4.3m ($5.5m), will be implemented over a three-year period as part of a wider £26m ($34.2m) financial commitment by Symbiosis to drive the growth of the company. The growth strategy includes the addition of automated sterile manufacturing production line capabilities to extend the commercial fill/finish services that Symbiosis offers its clients.